188 related articles for article (PubMed ID: 15254412)
1. Imatinib: paradigm or anomaly?
Druker BJ
Cell Cycle; 2004 Jul; 3(7):833-5. PubMed ID: 15254412
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.
Nadal E; Olavarria E
Int J Clin Pract; 2004 May; 58(5):511-6. PubMed ID: 15206509
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
Hernández-Boluda JC; Cervantes F
Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448
[TBL] [Abstract][Full Text] [Related]
5. Imatinib resistance in gastrointestinal stromal tumors.
Chen LL; Sabripour M; Andtbacka RH; Patel SR; Feig BW; Macapinlac HA; Choi H; Wu EF; Frazier ML; Benjamin RS
Curr Oncol Rep; 2005 Jul; 7(4):293-9. PubMed ID: 15946589
[TBL] [Abstract][Full Text] [Related]
6. STI571 (Gleevec) as a paradigm for cancer therapy.
Druker BJ
Trends Mol Med; 2002; 8(4 Suppl):S14-8. PubMed ID: 11927282
[TBL] [Abstract][Full Text] [Related]
7. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
Gambacorti C
Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608
[No Abstract] [Full Text] [Related]
8. Imatinib mesylate.
Waller CF
Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
[TBL] [Abstract][Full Text] [Related]
9. Recent advances of molecular targeted agents: opportunities for imaging.
Dancey JE
Cancer Biol Ther; 2003; 2(6):601-9. PubMed ID: 14688462
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal stromal tumours: etiology, pathology and clinical management.
Blackstein ME; Dubé P; Fletcher JA; Keller OR; Knowling M; Létourneau R; Morris D; Riddell R; Rorke S; Swallow CJ;
Can J Gastroenterol; 2004 Sep; 18 Suppl B():3B-8B. PubMed ID: 15457300
[TBL] [Abstract][Full Text] [Related]
11. STI571: a paradigm of new agents for cancer therapeutics.
Mauro MJ; O'Dwyer M; Heinrich MC; Druker BJ
J Clin Oncol; 2002 Jan; 20(1):325-34. PubMed ID: 11773186
[TBL] [Abstract][Full Text] [Related]
12. [Molecular target therapy for malignant tumors].
Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():76-80. PubMed ID: 15796061
[No Abstract] [Full Text] [Related]
13. Synthetic lethality: killing cancer with cancer.
Garber K
J Natl Cancer Inst; 2002 Nov; 94(22):1666-8. PubMed ID: 12441317
[No Abstract] [Full Text] [Related]
14. As targeted therapies evolve, challenges remain.
Benowitz S
J Natl Cancer Inst; 2004 Mar; 96(5):351-2. PubMed ID: 14996855
[No Abstract] [Full Text] [Related]
15. [Molecular targeted therapy for malignant brain tumors].
Okamura T; Kurisu K
Nihon Rinsho; 2005 Sep; 63 Suppl 9():520-6. PubMed ID: 16201575
[No Abstract] [Full Text] [Related]
16. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
Demetri GD
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386
[TBL] [Abstract][Full Text] [Related]
17. [STI571: a summary of targeted therapy].
Czyz M; Jakubowska J
Postepy Hig Med Dosw (Online); 2006; 60():677-96. PubMed ID: 17245318
[TBL] [Abstract][Full Text] [Related]
18. Combinations of targeted therapies take aim at multiple pathways.
Goldman B
J Natl Cancer Inst; 2003 Nov; 95(22):1656-7. PubMed ID: 14625255
[No Abstract] [Full Text] [Related]
19. Imatinib: a review of its use in chronic myeloid leukaemia.
Moen MD; McKeage K; Plosker GL; Siddiqui MA
Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate.
Waller CF
Recent Results Cancer Res; 2014; 201():1-25. PubMed ID: 24756783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]